Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2022/12/048270
CTRI/2022/12/048270Completed未知

A Double-Blind, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of Nasal Spray in Paediatric and Adolescent Subjects with Symptoms of Common Cold

ITC Life Sciences and Technology Centre0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1.Subjects with common cold symptoms.
  • •2.Subjects with cold symptom severity within the specified score range.
  • •3.Subject who agrees to give informed consent / assents and comply with the study procedures.

Exclusion Criteria

  • •1. Subjects with history/presence of clinically significant condition/disorder/allergy to herbal products (self-reported), or regularly consuming certain products as per invetigator judgement could interfere with the results of the study or the safety of the subject.
  • •2. Subjects tested positive for SARS-CoV-2 by Rapid Antigen Test.
  • •3. Subjects who test negative for viral load at baseline.
  • •4. Subjects with co-existing bacterial/secondary infections.
  • •5. Subjects having taken influenza vaccination within the last 3 months prior to screening visit.
  • •6.Subjects having common cold or flu like symptoms for > 48 hours.

Investigators

Sponsor
ITC Life Sciences and Technology Centre

Similar Trials

Completed
Not Applicable
Safety and Efficacy study of Nasal Spray on adults with common cold
CTRI/2021/09/036300ITC Life Sciences and Technology Centre120
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 100000004871
EUCTR2021-006069-39-DESanofi-Aventis Recherche & Développement190
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Parallel-Group Clinical Research Study to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care in comparison to Placebo Added to Standard of Care, in Non-Alcoholic Fatty Liver Disease (NAFLD) Connected with Type 2 Diabetes Mellitus (T2DM) and/or abnormally high levels of fats (lipids) in the blood (Hyperlipidemia) and/or abnormal accumulation of body fat (Obesity)on-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesityMedDRA version: 25.0Level: LLTClassification code 10082249Term: Nonalcoholic fatty liver diseaseSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2021-006069-39-PLSanofi-Aventis Recherche & Développement190
Not yet recruiting
Not Applicable
A Clinical Study to Evaluate the Efficacy and Safety of Viwithan in stressed Adult healthy Humans.
CTRI/2022/12/048354Vidya Herbs Pvt Ltd
Not yet recruiting
Not Applicable
A Randomized, Clinical Study to evaluate Efficacy and Safety of ONLP-15 in the Management of Cardio Vascular disease risk factors
CTRI/2022/02/039981Olene Life Sciences Private Limited